CYTH Stock Overview A clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. More details
Rewards Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Cyclo Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cyclo Therapeutics Historical stock prices Current Share Price US$0.63 52 Week High US$2.12 52 Week Low US$0.57 Beta -0.50 1 Month Change -13.70% 3 Month Change -9.61% 1 Year Change -66.49% 3 Year Change -83.97% 5 Year Change -97.90% Change since IPO -99.69%
Recent News & Updates
New major risk - Financial position Nov 17
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 17
Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules Oct 10
Insufficient new directors Oct 01 Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc. Sep 10
Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH). See more updates
New major risk - Financial position Nov 17
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 17
Cyclo Therapeutics Receives Two Letters from Nasdaq Due to Non-Compliance with Multiple Nasdaq Listing Rules Oct 10
Insufficient new directors Oct 01 Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc. Sep 10
Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).
New minor risk - Share price stability Aug 22
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 16 Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc. Jun 13
Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1 May 31
Consensus EPS estimates fall by 12% May 26
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 17
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 19
New minor risk - Profitability Mar 18 Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million. Dec 29
Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1 Dec 19 Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b) Dec 01
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 17
New major risk - Share price stability Nov 09
CEO & Director exercised options to buy US$293k worth of stock. Oct 25
Consensus revenue estimates decrease by 29%, EPS upgraded Sep 28
Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million. Sep 23 Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million. Sep 22
Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board Aug 22
New major risk - Revenue size Aug 17
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 16 Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc. Aug 03
Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023 Jun 14
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 14
Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director May 06
CEO & Director recently bought US$213k worth of stock Apr 25
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 19
Cyclo Therapeutics, Inc. Provides Clinical Program Update Jan 12
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease Jan 10
Consensus forecasts updated Nov 17
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 12
Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Oct 19
Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease Oct 06
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 17
Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M Aug 16
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation Jul 12
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022 May 02
Price target decreased to US$10.00 Apr 27
Consensus revenue estimates increase by 16% Apr 06
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 12
Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022 Feb 09
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate Jan 20
Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease Dec 08
Independent Vice Chairman recently bought US$53k worth of stock Nov 20
Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020) Nov 18
Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease Nov 16
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely? Sep 28
Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020) Aug 18
Consensus forecasts updated Jun 19
Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1 Jun 18
Cyclo Therapeutics Provides Update on Trappsol® Cyclo Jun 16
Cyclo therapeutics to join Russell 2000 Index Jun 14
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate Jun 12
Cyclo Therapeutics Provides Business Update May 18
First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020) May 16
Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1 Apr 28
Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo Apr 27
Independent Chairman recently bought US$81k worth of stock Mar 31
Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019) Mar 14
Earnings beat expectations, revenue disappoints Mar 14 Shareholder Returns CYTH US Biotechs US Market 7D 8.6% -3.6% -2.4% 1Y -66.5% -2.6% 23.4%
See full shareholder returns
Return vs Industry: CYTH underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CYTH underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is CYTH's price volatile compared to industry and market? CYTH volatility CYTH Average Weekly Movement 11.0% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CYTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.
Show more Cyclo Therapeutics, Inc. Fundamentals Summary How do Cyclo Therapeutics's earnings and revenue compare to its market cap? CYTH fundamental statistics Market cap US$18.12m Earnings (TTM ) -US$24.80m Revenue (TTM ) US$870.73k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CYTH income statement (TTM ) Revenue US$870.73k Cost of Revenue US$76.25k Gross Profit US$794.48k Other Expenses US$25.59m Earnings -US$24.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.86 Gross Margin 91.24% Net Profit Margin -2,848.16% Debt/Equity Ratio -90.4%
How did CYTH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 13:02 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cyclo Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Lucas Ward Ascendiant Capital Markets LLC Swayampakula Ramakanth H.C. Wainwright & Co. Jason McCarthy Maxim Group
Show 0 more analysts 
